Oliver W. Press

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Clinical Research Division
MemberAppointed: 1996
Fred Hutchinson Cancer Research Center
Lymphoma Research
Penny L. Peterson Endowed ChairAppointed: 2001
University of Washington Medical Center
Medicine
ProfessorAppointed: 1996
Professional Headshot of Oliver W. Press

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
P.O. Box 19024
D3-190
Seattle, Washington 98109-1024
United States

Contact Information

Phone: (206) 667-1864
Fax: (206) 667-1874
press@u.washington.edu

Qualifications

M.D., University of Washington, Medical Scientist Training Program, 1979.
Ph.D., University of Washington, Biological Structure, 1977.
B.S., Stanford University, Biology, 1973.

Expertise and Research Interests

My program is devoted to the investigation of novel treatments for hematologic malignancies including non-Hodgkin's lymphoma and acute and chronic leukemias. We conduct basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, we are continuing our successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and have trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.

Other Expertise

Postgraduate Training in Internal Medicine:
Fellow in Oncology, University of Washington/Fred Hutchinson Cancer Research Center, 1983-1986
Chief Residency, University of Washington Medical Center, Seattle, 1982-1983
Residency, Massachusetts General Hospital, Boston, 1980-1982
Internship, Massachusetts General Hospital, Boston, 1979-1980

Board Certification:
Medical Oncology Certification (A.B.I.M.), November, 1985
American Board of Internal Medicine, Sept. 15, 1982
National Board of Medical Examiners, July 1, 1980

Licensure:
State of Washington, #20170 (8/6/82).

Editorial Positions:
Associate Editor, Journal of the National Cancer Institute, 1991-1995
Managing Editor, annals of Hematology, 1998-2001
Editor, Blood, 2001-present
Editor, Journal of Therapeutic Immunology, 1995-1999
Editor, Advances in Leukemia/Lymphoma
Editor, Tumor Targeting
Editor, Cancer Biotherapy and Radiopharmaceuticals
Editor, Cytokines, Cellular & Molecular Therapy
Reviewer, Cancer Research/Clinical Cancer Research/Journal of Immunology/Journal of Clinical Oncology/Blood/Chest.

Keywords

COS Keywords:

Cancer Or Carcinogenesis, Immunobiology, Immunology, Immunotherapy, Oncology, Tumor Immunology.

Additional Terms:

Cancer, Cancer Therapy, Cancer Treatment, Immunobiology, Immunology, Immunotherapy, Oncology, Radiation Biology, Specific Cancers, Tumor Biology.

Memberships

American Association for Cancer Research
American Association of Physicians
American Federation for Clinical Research, Councilor for Washington
American Medical Association
American Society for Clinical Investigation
American Society for Clinical Oncology
American Society for Gene Therapy
American Society of Hematology
Southwest Oncology Group

Honors and Awards

2009, Co-Chair, Lymphoma Steering Committee, National Cancer Institute
2007, Ellen Glesby Cohen Leadership Award, Lymphoma Research Foundation
2005, Chairman, Scientific Advisory Board, Lymphoma Research Foundation
2002, Selected as one of Seattle's 'Best Doctors', Seattle Magazine
2001-2003, Selected as one of 'America's Top Doctors',
2000, Election to the American Association of Physicians ('Old Turks'),
1998, CRS-Cygnus Award for Outstanding Work in Drug Delivery,
1996, Election to the American Society for Clinical Investigation ('Young Turks'),
1993-1995, Recipient of the first Boeing Corporate Medical Research Award,
1988-1989, Elsa Pardee Award for Cancer Research,
1987-1992, First Independent Research and Training Award from the National Institutes of Health,
1985-1986, Young Investigator Award from the American Society for Clinical Oncology,
1985-1988, Clinical Oncology Career Development Award from the American Cancer Society,
1979, PhD Thesis Honors, University of Washington
1979, Medical Auxiliary MD, PhD Award,
1979, Graduation with 'Highest Honors' from University of Washington School of Medicine,
1979, Robert S. Evans Award,
1979, John J. Bonica Prize in Anesthesiology,
1979, Lamport Biomedical Research Prize,
1979, Seattle Academy of Internal Medicine Prize,
1978, Scholarship from International College of Surgeons,
1976, Alpha Omega Alpha, Honorary Medical Fraternity (elected as 3rd year student in Spring, 1976),
1973, Phi Beta Kappa, Stanford University
1973, Departmental Honors and Departmental Distinction in Biology, Stanford University
1970-1973, George E. Gamble Honors Scholarship, Stanford University

Previous Positions

2005-2009, Clinical Research in Hematology and Hematologic Malignancies, Seattle Cancer Care Alliance
1996-2007, Biological Structure, University of Washington, Biological Structure
1993-2000, Acting Program Director, University of Washington Medical Center, High-Dose Chemotherapy Unit
1991-1996, Associate Member, Fred Hutchinson Cancer Research Center
1991-2006, Associate Director, University of Washington, Medical Scientist Training Program
1991-1996, Associate Professor in Medicine, University of Washington
1991-2006, Associate Director, Medical Scientist Training Program, University of Washington, School of Medicine
1988-1991, Adjunct Assistant Professor of Biological Structure, University of Washington
1987-1991, Assistant Professor in Medicine, University of Washington
1986-1991, Assistant Member, Fred Hutchinson Cancer Research Center
1983-1986, Senior Fellow, Fred Hutchinson Cancer Research Center
1982-1986, Acting Instructor in Medicine, University of Washington
1979-1982, Clinical Fellow in Medicine, Harvard University, Medical School

Funding Received

  • Lymphoma Research Foundation: Optimizing Adoptive T Cell Immunotherapy for Mantle Cell Lymphoma, 2007 to 2010.
  • National Institutes of Health (NIH): CD45 Pretargeted Radioimmunotherapy for AML, 2004 to 2008.
  • Leukemia and Lymphoma Society of America: Allogeneic Transplantation for Lymphomas and Leukemias Using Reduced Intensity Conditioning Regimens Containing Radiolabeled Anti-CD20 and Anti-CD45 Monoclonal Antibodies, 2002 to 2007.
  • National Institutes of Health (NIH): Chimeric Anti-CD20 T Cell Receptors for Lymphoma Therapy, 2001 to 2006.
  • National Institutes of Health (NIH): Pretargeted Radioimmunotherapy of CD20+ NHL, 1998 to 2012.
  • National Institutes of Health (NIH): Therapy of Lymphoma/Leukemia with Monoclonal Antibodies, 1988 to 2010.

Publications

  • Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur DS, Fisher DR, Rajendran JG, Gopal AK, Park SI, Press OW (Aug 2009) Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates., Blood, 114 (6), 1226-35 Abstract
  • Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW (Jun 2009) 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma., Blood, 113 (23), 5905-10 Abstract
  • Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW (May 2009) A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations., Blood, 113 (20), 4903-13 Abstract
  • Sharkey RM, Press OW, Goldenberg DM (Apr 2009) A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy., Blood, 113 (17), 3891-5 Abstract
  • Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM (Mar 2009) Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211., Cancer research, 69 (6), 2408-15 Abstract
  • Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Appelbaum FR, Press OW (Jan 2009) Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia., Cancer research, 69 (1), 185-92 Abstract
  • Press OW (Nov 2008) Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 (32), 5147-50 Abstract
  • Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, Bensinger WI (Oct 2008) High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma., Leukemia & lymphoma, 49 (10), 1899-906 Abstract
  • Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM (Aug 2008) Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab., Blood, 112 (3), 830-5 Abstract
  • Gopal AK, Metcalfe TL, Gooley TA, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG, Press OW (Jul 2008) High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience., Cancer Abstract
  • Buchegger F, Press OW, Delaloye AB, Ketterer N (Jun 2008) Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma., The oncologist, 13 (6), 657-67 Abstract
  • Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW (May 2008) Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose., Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 49 (5), 837-44 Abstract
  • James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW (May 2008) Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane., Journal of immunology (Baltimore, Md. : 1950), 180 (10), 7028-38 Abstract
  • Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW (May 2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells., Blood Abstract
  • Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur DS, Nilsson R, Sandberg B, Press OW (Apr 2008) Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies., Cancer biotherapy & radiopharmaceuticals, 23 (2), 181-91 Abstract
  • Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A (Apr 2008) Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz, Blood, 111 (8), 4048-54 Abstract
  • Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F (Apr 2008) Non-Hodgkin's lymphomas., Journal of the National Comprehensive Cancer Network : JNCCN, 6 (4), 356-421 Abstract
  • Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger W, Press OW (Apr 2008) Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma., Leukemia & lymphoma, 1-12 Abstract
  • Pagel JM, Hedin N, Drouet L, Wood BL, Pantelias A, Lin Y, Hamlin DK, Wilbur DS, Gopal AK, Green D, Appelbaum FR, Press OW (Feb 2008) Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy., Blood, 111 (4), 2261-8 Abstract
  • Pham RN, Gooley TA, Keeney GE, Press OW, Pagel JM, Greisman HA, Bensinger WI, Holmberg LA, Petersdorf SH, Maloney DG, Gopal AK (Dec 2007) The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma., Bone marrow transplantation, 40 (11), 1039-44 Abstract
  • Park SI, Press OW (Nov 2007) Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies., Current opinion in hematology, 14 (6), 632-8 Abstract
  • Keeney GE, Gooley TA, Pham RN, Press OW, Pagel JM, Petersdorf SH, Maloney DG, Bensinger W, Holmberg L, Gopal AK (Oct 2007) The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation., Leukemia & lymphoma, 48 (10), 1961-7 Abstract
  • Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH (Sep 2007) Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate., Blood, 110 (6), 2049-56 Abstract
  • Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal A, Hamlin DK, Press OW (Sep 2007) Pretargeted radioimmunotherapy for B-cell lymphomas., Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (18 Pt 2), 5598s-5603s Abstract
  • Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, Till B, Raubitschek A, Forman SJ, Qian X, James S, Greenberg P, Riddell S, Press OW (Aug 2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains., Human gene therapy, 18 (8), 712-25 Abstract
  • Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Lin Y, Stone D, Axworthy D, Gopal AK, Press OW (Jun 2007) Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas., Blood, 109 (11), 4980-7 Abstract
  • Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW (Jun 2007) Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas., Cancer research, 67 (12), 5921-8 Abstract
  • Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW (Apr 2007) High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 (11), 1396-402 Abstract
  • Gopal AK, Pagel JM, Rajendran JG, Maloney DG, Appelbaum FR, Sorror ML, Sandmaier BM, Storb R, Press OW (Jul 2006) Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 (7), 697-702 Abstract
  • Lilleby K, Garcia P, Gooley T, McDonnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W (2006) A Prospective, Randomized Study of Cryotherapy During Administration of High-dose Melphalan to Decrease the Severity and Duration of Oral Mucositis in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation., Bone Marrow Transplant, 37 (11), 1031-1035
  • Gopal AK, Pagel JM, Rajendran JG, Maloney DG, Appelbaum FR, Sorror ML, Sandmaier BM, Storb R, Press OW (2006) Improving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma Using Radioimmunotherapy., Biol Blood Marrow Transplant, 12 (7), 697-702
  • Press OW (2006) Phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I-131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911., Journal of Clinical Oncology, 24, 4143
  • Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI (2006) Phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I-131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911., Journal of Clinical Oncology, 24, 4143
  • Pagel JM, Axworthy D, Hedin N, Theodore LJ, Wilbur DS, Press OW (2006) Comparison of a Tetravalent Single-Chain Antibody-Streptavidin Fusion Protein and an Antibody-Streptavidin Chemical Conjugate in Pretargeted Anti-CD20 Radioimmunotherapy of B-cell Lymphomas, Blood, 108 (1), 328-336
  • Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW (2006) A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Proteinfor Pretargeted Radioimmunotherapy of Hematologic Malignancies, Cancer Research, 66 (7), 3884-3892
  • Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Martin PJ, Gooley T, Press OW, Bernstein ID, Matthews DC (2006) I-131-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission., Blood, 107 (5), 2184-2191
  • Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW (Jul 2005) Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research., 11 (13), 4857-66 Abstract
  • Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL (Jun 2005) Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab., Blood, 105 (12), 4576-82 Abstract
  • Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK (May 2005) Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 23 (15), 3439-46 Abstract
  • Fisher RI, LeBlanc M, Press OW (2005) New Treatment Options Have Changed the Survival of Patients with Follicular Lymphoma., J. Clin. Oncol., 23, 8447-52
  • Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC (Jan 2005) Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research., 11 (2 Pt 1), 787-94 Abstract
  • Sui X, Bensinger W, Press O (2005) Improved conditioning regimens for autologous transplantation using targeted radiotherapy., Acta Haematologica, 114 (4), 230-8 Abstract
  • Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, Stayton PS (Jan-Feb 2005) Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma., Bioconjugate Chemistry, 16 (1), 131-8 Abstract
  • Rajendran J, Gopal A, Durack L, Fisher D, Press O, Eary J (Dec 2004) Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma., Cancer Biotherapy & Radiopharmaceuticals, 19 (6), 738-45 Abstract
  • Epstein JB, Truelove EL, Hanson-Huggins K, Mancl LA, Chen A, Press OW, Petersdorf SH, Fritsche TR, Epstein JD (Jul 2004) Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy., Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer., 12 (7), 517-25 Abstract
  • Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF (Jun 2004) High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine., 45 (6), 1059-64 Abstract
  • Gopal AK, Pagel JM, Hedin N, Press OW (May 2004) Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism., Blood, 103 (9), 3516-20 Abstract
  • Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC (Apr 2004) Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes., Molecular Therapy : the Journal of the American Society of Gene Therapy, 9 (4), 577-86 Abstract
  • Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, and Press OW (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: A multivariable cohort analysis, Blood, 102 (7), 2351-7
  • Ganz PA, Moinpour CM, Pauler D, McCoy S, Kornblith AB, Press OW, and Fisher R (2003) Health Status and Quality of Life in Patients with Early Stage Hodgkin's Disease Treated on SWOG-9133, Journal of Clinical Oncology, 15 (18), 3512-9
  • Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, and Press OW, A comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas, Blood, 101(6), 2340-2348, 15 Mar 2003
  • Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, and Press OW, Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts, Journal of Nuclear Medicine, 44(3), 437-445, March 2003
  • Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, and Fisher RI (2003) A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group Protocol S9911, Blood, 102 (5), 1606-12
  • Wilbur DS, Hamlin DK, Meyer DL, Mallett RW, Quinn J, Vessella RL, Press OW, Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin, Bioconjugate Chemistry, 13(3), 611-20, 2002 Abstract
  • Lackey CA, Press OW, Hoffman AS, and Stayton PS, A bioimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex, Bioconjugate Chemistry, 13(5), 996-1001, 2002
  • Hamblett KJ, Kegley BB, Hamlin DK, Chyan M-K, Hyre DE, Press OW, Wilbur DS, and Stayton PS, A streptavidin-biotin binding system that minimizes blocking by endogenous biotin, Bioconjugate Chemistry, 13(3), 588-98, 2002
  • Gopal AJ, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, and Press OW, High dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma, Blood, 99, 3158-3162, 2002
  • Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI, Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 19(22), 4238-44, November 2001 Abstract
  • Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, Theodore L, Yau E, Mallett R, Meyer DL, Axworthy D, A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts, Blood, 98(8), 2535-43, October 2001 Abstract
  • Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 19(19), 3918-28, October 2001 Abstract
  • Shan D, Gopal AK, Press OW, Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells, Clinical Cancer Research : an Official Journal of the American Association for Cancer Research., 7(8), 2490-5, August 2001 Abstract
  • Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH, Appelbaum FR, Press OW, Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older, Bone Marrow Transplantation, 27(6), 593-9, March 2001 Abstract
  • Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, Anasetti C, Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells, Journal of Immunology (baltimore, Md. : 1950), 165(11), 6205-13, December 2000 Abstract
  • Press OW, Rasey J, Principles of radioimmunotherapy for hematologists and oncologists, Seminars in Oncology, 27(6 Suppl 12), 62-73, December 2000 Abstract
  • Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID, A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, Blood, 96(9), 2934-42, November 2000 Abstract
  • Press OW, Emerging immunotherapies for non-Hodgkin lymphomas: the tortoise approaches the finish line, Annals of Internal Medicine, 132(11), 916-8, June 2000 Abstract
  • Shan D, Ledbetter JA, Press OW, Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells, Cancer Immunology, Immunotherapy : Cii, 48(12), 673-83, March 2000 Abstract
  • Johnson TA, Press OW, Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas, International Journal of Cancer. Journal International Du Cancer, 85(1), 104-12, Jan 2000 Abstract
  • Carpenter PA, Tso JY, Press OW, Yu X, Anasetti C, Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo, Transplant Proc., 32, 1545-1546, 2000
  • Park JM, Yang X, Park JJ, Press OW, Press MF, Assessment of novel anti-p185HER-2 monoclonal antibodies for internalization-dependent therapies, Hybridoma, 18(6), 487-95, December 1999 Abstract
  • Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA, Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths., Journal of Immunology, 162(11), 6589-95, 1 Jun 1999 Abstract
  • Press O W, Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates., Cancer Journal From Scientific American, 4 Suppl 2, S19-26, July 1998 Abstract
  • Shan D, Ledbetter J A, Press O W, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies., Blood, 91(5), 1644-52, 1 Mar 1998 Abstract
  • Zhan J, Stayton P, Press O W, Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation., Cancer Immunology, Immunotherapy, 46(1), 55-60, March 1998 Abstract
  • Press O W, LeBlanc M, O'Rourke T J, Gagnet S, Chapman R A, Balcerzak S P, Fisher R I, Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246., Journal of Clinical Oncology, 16(2), 574-8, February 1998 Abstract
  • Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley T, Bernstein ID, Press OW, Follow-up of relapsed B cell lymphoma patients treated with I-131-labeled anti-CD20 antibody and autologous stem cell rescue, Journal of Clinical Oncology, 16, 3270-3278, 1998
  • Press O W, Shan D, Howell-Clark J, Eary J, Appelbaum F R, Matthews D, King D J, Haines A M, Hamann P, Hinman L, Shochat D, Bernstein I D, Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells., Cancer Research, 56(9), 2123-9, 1 May 1996 Abstract
  • Bilge A, Warner C V, Press O W, Translocation of ricin A-chain into proteoliposomes reconstituted from Golgi and endoplasmic reticulum., Journal of Biological Chemistry, 270(40), 23720-5, 6 Oct 1995 Abstract
  • Press O W, Eary J F, Appelbaum F R, Martin P J, Nelp W B, Glenn S, Fisher D R, Porter B, Matthews D C, Gooley T, et al, Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas., Lancet, 346(8971), 336-40, 5 Aug 1995 Abstract
  • Shan D, Press O W, Constitutive endocytosis and degradation of CD22 by human B cells., Journal of Immunology, 154(9), 4466-75, 1 May 1995 Abstract
  • Bilge A, Howell-Clark J, Ramakrishnan S, Press O W, Degradation of ricin A chain by endosomal and lysosomal enzymes--the protective role of ricin B chain., Therapeutic Immunology, 1(4), 197-204, August 1994 Abstract
  • Press O W, Howell-Clark J, Anderson S, Bernstein I, Retention of B-cell-specific monoclonal antibodies by human lymphoma cells., Blood, 83(5), 1390-7, 1 Mar 1994 Abstract
  • De Santes K, Slamon D, Anderson S K, Shepard M, Fendly B, Maneval D, Press O, Radiolabeled antibody targeting of the HER-2/neu oncoprotein., Cancer Research, 52(7), 1916-23, 1 Apr 1992 Abstract
  • Matthews D C, Appelbaum F R, Eary J F, Hui T E, Fisher D R, Martin P J, Durack L D, Nelp W B, Press O W, Badger C C, et al, Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque., Blood, 78(7), 1864-74, 1 Oct 1991 Abstract
  • Press O W, Livingston R, Mortimer J, Collins C, Appelbaum F, Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation., Journal of Clinical Oncology, 9(3), 423-31, March 1991 Abstract
  • Eary J F, Press O W, Badger C C, Durack L D, Richter K Y, Addison S J, Krohn K A, Fisher D R, Porter B A, Williams D L, et al, Imaging and treatment of B-cell lymphoma [see comments], Journal of Nuclear Medicine, 31(8), 1257-68, August 1990 Abstract
  • Ali S A, Warren S D, Richter K Y, Badger C C, Eary J F, Press O W, Krohn K A, Bernstein I D, Nelp W B, Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts., Cancer Research, 50(3 Suppl), 783s-788s, 1 Feb 1990 Abstract
  • Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ, Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies, Cancer Research, 49(17), 4906-12, September 1989 Abstract
  • Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, et al., Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 7(8), 1027-38, August 1989 Abstract
  • Press OW, Martin PJ, Thorpe PE, Vitetta ES, Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells, Journal of Immunology (baltimore, Md. : 1950), 141(12), 4410-7, December 1988 Abstract
  • Press OW, Hansen JA, Farr A, Martin PJ, Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes, Cancer Research, 48(8), 2249-57, April 1988 Abstract
  • Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas, Blood, 69(2), 584-91, February 1987 Abstract
  • Press OW, Livingston R, Management of malignant pericardial effusion and tamponade, JAMA: The Journal of the American Medical Association, 257(8), 1088-92, February 1987 Abstract
  • Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO, Hickman catheter infections in patients with malignancies, Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatries., 63(4), 189-200, July 1984 Abstract
  • Press OW, Ramsey PG, Central nervous system infections associated with hereditary hemorrhagic telangiectasia, The American Journal of Medicine, 77(1), 86-92, July 1984 Abstract
  • Press OW, Press NO, Kaufman SD, Evaluation and management of chylous ascites, Annals of Internal Medicine, 96(3), 358-64, March 1982 Abstract
  • Press OW, Rosse C, Clagett J, Phytohemagglutinin-induced differentiation and blastogenesis of precursor T cells from mouse bone marrow, Journal of Experimental Medicine, 146(3), 735-46, September 1977 Abstract
  • Press OW, Eary J, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews D, Fisher L, Bernstein ID. Radiolabeled Antibody Therapy of B Cell Lymphomas with Autologous Bone Marrow Support. New Engl J Med 324: 1219-1224, 1993
  • Press OW, DeSantes KD, Anderson SK, Geissler F. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. Cancer Res 50: 1243-1250, 1990

Profile Details

Last Updated: 8/13/2009

COS Expertise ID #308584
Reference this profile directly: http://myprofile.cos.com/presso84